Persistence of bcr-abl transcripts after marrow grafting is thought to convey a high risk for relapse in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). Donor leukocyte infusion (DLI) is closely associated with development of graftversus-host disease (GVHD) and has well-defined activity against relapsed chronic myelogenous leukemia (CML) but not ALL. We report two patients with Phpositive ALL who remained bcr-abl positive by reverse transcriptase polymerase chain reaction (RT-PCR) after marrow grafting. Residual bcr-abl transcripts in both patients were eliminated following acute GVHD, which was induced by either DLI or rapid reduction of immunosuppression. Both patients have continued in complete molecular remission for 18 months and 8 months following transplantation, respectively. Our observation suggests that induction of GVHD may eliminate minimal residual disease, thereby preventing leukemia relapse in patients transplanted for Ph-positive ALL. Bone Marrow Transplantation (2002) 29, 63-66. DOI: 10.1038/sj/bmt/1703318 Keywords: bcr-abl; MRD; Ph-positive ALL; DLI; stem cell transplantation; GVL The prognosis of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) is much worse than other types of ALL in both children and adults.
Although most patients with Ph-positive ALL will achieve a complete clinical remission after induction chemotherapy, their long-term survival has remained poor because of a high rate of relapse. 6 Allogeneic marrow transplant has yielded only a 38% disease-free survival rate for patients with Ph-positive ALL transplanted in first complete remission (CR). 7 Persistent positivity for bcr-abl mRNA after marrow grafting is associated with an increased risk of subsequent relapse. 8, 9 We report two patients with Ph-positive ALL who remained bcr-abl positive after stem cell transplantation; bcr-abl negativity was successfully achieved by inducing acute GVHD either by DLI or rapid withdrawal of immunosuppression. Both patients remain in complete hematologic and molecular remission after 18 and 8 months.
Materials and methods

Reverse transcriptase-polymerase chain reaction (RT-PCR) for detection of bcr-abl transcripts
RT-PCR was performed as previously described. 8, 9 Briefly, total cellular RNA was isolated from bone marrow mononuclear cells using the guanidine isocyanate phenol/ chloroform method. PCR was performed using a DNA Thermal Cycler (Labocycler, Stratagene, La Jolla, CA, USA) for a total of 30 cycles under the conditions recommended by the supplier. As a positive control, a second RT-PCR was performed on the same sample using ablspecific primers.
Quantitative real-time PCR
Real-time quantitative PCR was performed as previously described. 10 Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an active endogenous reference. The normalized bcr-abl dose was defined as the expression level of bcr-abl divided by the GAPDH expression level.
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Case reports
Patient 1
A 49-year-old male was referred to Kameda General Hospital in November 1999 because of fever and anemia and was diagnosed as having Ph-positive ALL. Cytogenetic study showed the t(9;22)(q23;q21) and the minor bcr-abl transcript was detected by RT-PCR. He received induction chemotherapy according to the Japan Leukemia Study Group (JALSG) ALL-90 protocol 11 and entered CR in January 2000. Because of the poor prognosis of adult Phpositive ALL, he received a peripheral blood stem cell transplant (PBSCT) from his HLA-matched sister in March 2000. Twelve Gy of fractionated total body irradiation (TBI) in six doses for 3 days, cyclophosphamide 60 mg/kg for 2 days, and cytarabine 2 g/m 2 for 2 days were given as the preparative regimen followed by 5.2 × 10 6 /kg CD34 + G-CSF-mobilized peripheral blood stem cells. GVHD prophylaxis consisted of cyclosporin A (CyA) and shortterm methotrexate (MTX). Engraftment was confirmed by the rise in blood cell counts and by sex chromosome analysis on day 14 after transplantation. Although cytogenetic analysis of bone marrow showed normal 46,XX karyotype, persisting positivity of minor bcr-abl by RT-PCR was observed ( Figure 1 ). CyA was rapidly tapered and stopped by day 56 in an attempt to induce GVHD, but this was unsuccessful. We therefore decided to administer DLI to eradicate the residual Ph-clone by inducing GVL. On day 135, the patient received the first DLI containing 0.3 × 10 7 /kg CD3 + cells and on day 145, he received a second DLI of 1.0 × 10 7 /kg CD3 + cells. Acute GVHD grade III developed on day 155 and was successfully treated by high-dose methylprednisolone followed by a combination of CyA and prednisolone. RT-PCR of the minor bcr-abl became negative on day 156 and remained negative on days 182, 256 and 392 after transplant. Although he suffered from recurrent hemorrhagic cystitis due to adenovirus type 11 for the next 8 months after transplant, he continues in hematologic CR with mild chronic GVHD for 18 months after transplant.
Patient 2
A 60-year-old female was diagnosed as having Ph-positive ALL at routine examination on April 2000. The patient had t(9;22)(q11;q34) with both minor and major bcr-abl mRNA. Treatment with the L10/M 17 protocol 12 and two courses of hyper-CVAD 13 as salvage therapy were unsuccessful. She was referred to our hospital for unrelated allogeneic BMT using the Japan Marrow Donor Program (JMDP). At the time of referral, her hemoglobin was 7.8 g/dl, platelets 12 × 10 9 /l and WBC 120 × 10 9 /l with 92% blasts. Her marrow was hypercellular with 87% blasts and RT-PCR showed positivity of the major bcr-abl alone. Quantitative real-time PCR of the major bcr-abl transcript was 940 000 copies/g RNA. On 19 December 2000 she received an HLA-matched unrelated marrow transplant following a conditioning regimen of 8 Gy of fractionated TBI with lung shielding and 60 mg/kg/day cyclophosphamide for 2 days. Short-term MTX and CyA were used for prophylaxis of GVHD. Although atypical blasts were noted in the bone marrow smear after grafting, donor cell engraftment was confirmed by the rise in blood count and by a variable number of tandem repeat (VNTR) analysis by day 14. Cytogenetic analysis showed a normal female karyotype on day 21 after BMT, but bcr-abl remained positive by RT-PCR. Quantitation of the major bcr-abl transcript by real-time PCR decreased to 640 copies/g RNA on day 21 simultaneously with the development of acute GVHD grade II. The amount of bcr-abl transcripts reincreased to 1100 copies/g RNA on day 26 with resolution of GVHD after prednisolone (Figure 1 ). We then tapered both CyA and steroid rapidly and stopped them on day 35 in an attempt to reinduce a GVL effect. On day 46, she developed grade III acute GVHD characterized by high fever, generalized skin rash and diarrhea. She received high-dose methylprednisolone (1.0 g/day) for 3 days, which was then tapered gradually. GVHD subsided promptly and bcr-abl transcripts became undetectable on day 51 by RT-PCR. Serial analysis of the major bcr-abl by RT-PCR continued to be negative 8 months post BMT. She remains in complete remission with extensive chronic GVHD that is treated by alternating CyA and prednisolone.
Discussion
Treatment of Ph-positive ALL has improved only marginally despite the use of modern chemotherapy and supportive care. 11, 14 Even with more aggressive treatment such as BMT, relapse is still the major cause of death in Phpositive ALL. 7 Since leukemic relapse is thought to arise from minimal residual disease (MRD), monitoring of MRD by PCR after BMT appears to be a useful tool for predicting which will be high-risk patients. 8, 9, 15 Miyamura et al 8 and Radich et al 9 reported the predictive value of a positive bcr-abl mRNA by PCR after transplant. Both of our patients with repeatedly positive bcr-abl by RT-PCR were clearly at high risk for relapse. Patient 1 showed minor bcrabl positivity after transplant which was effectively treated by DLI. A similar case was reported by Yazaki et al 16 with successful treatment by three courses of DLI. Although the anti-leukemia potential of DLI in patients with ALL has been described, [16] [17] [18] [19] [20] DLI was thought to have limited benefit in patients with relapsed ALL after BMT. Kolb et al 21 and Collins et al 22 reported poor outcomes in ALL patients given DLI after relapse. The reason for low efficacy of DLI in ALL is uncertain. However, it may be possible that the leukemia burden is too high at relapse to be eradicated by DLI. Thus, it appears essential to give DLI in the earliest stage of relapse. In the case of patient 2 who was refractory to previous chemotherapies, and was treated with an unrelated bone marrow transplant, we gave a slightly reduced TBI dose (8 Gy, usually 12 Gy) with lung shielding in view of her previous chemotherapies and age. As a consequence, she showed persistent major bcr-abl positivity after marrow grafting. Furthermore, control of her acute GVHD resulted in a rise in the major bcr-abl transcripts which is reported to be associated with relapse in patients with CML. 23, 24 We therefore assumed that this patient might have impending relapse. Rapid tapering of steroids and CyA resulted in acute GVHD and led to molecular remission. In both patients, the disappearance of MRD coincided with the development of acute GVHD induced by either DLI or withdrawal of immunosuppression. Despite the limited benefit of DLI in patients with ALL after marrow grafting, the GVL effect associated with GVHD in ALL has been well documented by a number of studies. 25 Passweg et al 26 analyzed IBMTR data and reported a lower relapse risk in ALL patients with GVHD after BMT. Recently, Cornelissen et al 27 suggested a susceptibility to the GVL effect in patients with Ph-positive ALL compared to ALL patients with t(4;11) or t (1;19) . Together with these previous reports, our current observations suggest that the GVL effect may eliminate or suppress residual leukemia clones in ALL patients, thereby maintaining remission after transplant.
In conclusion, we successfully eliminated residual bcr-abl clones by inducing a GVL effect before there was evidence of clinical relapse, by monitoring for MRD by RT-PCR. Although the observation period is too short for definitive conclusions, induction of GVHD by DLI or withdrawal of immunosuppression are promising modalities for prevention of relapse in patients with Ph-positive ALL and persistent MRD.
